SOPHiA GENETICS reported strong financial results for the second quarter ended June 30, 2025, with revenue growing 16% year-over-year to $18.323 million. This growth was driven by new business ramping up and the adoption of transformative applications like MSK-ACCESS® powered with SOPHiA DDM™.
The company demonstrated continued operational efficiency, expanding adjusted gross margins by 120 basis points year-over-year to 74.4%, despite increased data volume. Cash burn notably decreased to $8.7 million in the quarter, representing a 35% improvement year-over-year, supported by prudent cost management.
SOPHiA GENETICS signed an all-time high of 35 new core genomics customers in Q2 and announced the largest contract in company history: a multi-year AI breast cancer partnership with AstraZeneca. The company also drew an additional $35 million from its debt financing facility, bringing cash and cash equivalents to $94.8 million as of June 30, 2025, and reaffirmed its 2025 revenue and adjusted EBITDA loss guidance.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.